You are here: Industry Insights > PD-L1

News List

Abcam, Merck Launch Anti-PD-L1 Antibody Clone contractpharma
July 03, 2018
Abcam announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany.
Anti-PD-1/PD-L1 Monoclonal Antibodies: Not Easy to Let Go (2) Mr. Nanguo
May 02, 2018
Whether products have unique advantages is a criterion for considering whether they can be further advanced.
Anti-PD-1/PD-L1 Monoclonal Antibodies: Not Easy to Let Go (1) Mr. Nanguo
May 02, 2018
Anti-PD-1/PD-L1 monoclonal antibodies, the trailbreaker of tumor immunotherapies, have been chased after by the market since marketing, and become the battleground of international pharmaceutical giants.
The Most Comprehensive Summary Ever! About the Chinese-produced Anti-PD-1/PD-L1 Drugs Caicai
April 13, 2018
The anti-PD-1 monoclonal antibody JS001 of Junshi has been completed the first patient administration of Phase I clinical trial in the U.S. several days ago, which has aroused wide attention from the insiders.
Independent research may change the immunotherapy game pharmafile
August 18, 2017
Treatments are so successful, in certain patients, that they’ve become an extremely lucrative market – so much so that AstraZeneca’s fortunate were sunk on the poor result of one combination trial with its own PD-L1 inhibitor, Imfinzi.
Agilent Technologies announces expanded use for PD-L1 IHC 28-8 pharmDx diagnostic in Europe biospectrumasia
May 16, 2017
Approved for use in Europe to identify head and neck Cancer patients most likely to benefit from Opdivo (nivolumab) Therapy

Previous page 1 2 3 4 5 Next page